Product Description
Amikacin injection is used to treat serious bacterial infections in many different parts of the body. Amikacin belongs to the class of medicines known as aminoglycoside antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/amikacin-injection-route/side-effects/drg-20074493?p=1)
Mechanisms of Action: 30S Ribosomal Subunit Antagonist,Protein Synthesis Inhibitor,Gram- Bacteria Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Insmed
Company Location: BRIDGEWATER NJ 08807
Company CEO: William H. Lewis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Canada, Chile, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, New Zealand, Poland, Portugal, Rwanda, Spain, Taiwan, Turkey, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Communicable Diseases|Mycobacterium Infections, Nontuberculous|Mycobacterium avium-intracellulare Infection|Nontuberculous Mycobacterial Lung Disease
Phase 2: Mycobacterium Infections|Tuberculosis, Multidrug-Resistant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AKAPI | P2 |
Not yet recruiting |
Mycobacterium Infections |
2026-08-01 |
|
| INS-416 | P3 |
Unknown Status |
Nontuberculous Mycobacterial Lung Disease |
2026-06-15 |
|
| ENCORE | P3 |
Active, not recruiting |
Mycobacterium avium-intracellulare Infection|Mycobacterium Infections, Nontuberculous|Communicable Diseases |
2025-11-15 |
|
| Stake | P2 |
Recruiting |
Tuberculosis, Multidrug-Resistant |
2024-03-01 |